Alkermes announces initiation of phase 1 clinical study of ALKS 7106 for treatment of pain
Alkermes announced initiation of a phase 1 clinical study of ALKS 7106, a proprietary, novel, oral, small-molecule drug candidate for treatment of pain. The randomized, double-blind, placebo-controlled study will evaluate safety, tolerability and pharmacokinetics of ALKS 7106 in male adults. August 26, 2014